Clinical Trial

A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a randomized, parallel group, double-blind, active-controlled, clinical pharmacology study to compare Pharmacokinetics, Pharmacodynamics and safety of PB018 versus Ocrevus in patients with Multiple Sclerosis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-18.
Trial Details
NCT Number NCT07606521
Lead Sponsor Polpharma Biologics International AG
Conditions Multiple Sclerosis
Enrollment 222 participants
Start Date 2026-10
Primary Completion 2027-12 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-05-28